Céline Ségura‐Ferlay

405 total citations
10 papers, 276 citations indexed

About

Céline Ségura‐Ferlay is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Céline Ségura‐Ferlay has authored 10 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 3 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Céline Ségura‐Ferlay's work include Renal and related cancers (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Renal cell carcinoma treatment (2 papers). Céline Ségura‐Ferlay is often cited by papers focused on Renal and related cancers (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Renal cell carcinoma treatment (2 papers). Céline Ségura‐Ferlay collaborates with scholars based in France. Céline Ségura‐Ferlay's co-authors include David Pérol, H. Le Caer, Fabrice Barlési, B. Milleron, Miquel Tarón, Virginie Westeel, P. Fournel, Jacky Créquit, Gérard Zalcman and I. Monnet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Céline Ségura‐Ferlay

10 papers receiving 270 citations

Peers

Céline Ségura‐Ferlay

PRM

ONCOL

EDM

SURGE

Louise Flanagan United Kingdom

H. Al‐Abadi Germany

I. Toledano France

Smita Asare United States

Neus Basté Spain

Enza Di Felice Italy

Uriel Bohn Spain

Loretta Sullivan United States

Shi-Liang Liu China

M. Neubauer United States

Louise Flanagan United Kingdom

Céline Ségura‐Ferlay

58 ×0.3

PRM

109 ×0.7

ONCOL

32 ×0.6

EDM

36 ×0.8

SURGE

170 ×3.7

Citations per year, relative to Céline Ségura‐Ferlay Céline Ségura‐Ferlay (= 1×) peers Louise Flanagan

Countries citing papers authored by Céline Ségura‐Ferlay

Since Specialization

Citations

This map shows the geographic impact of Céline Ségura‐Ferlay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Ségura‐Ferlay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Ségura‐Ferlay more than expected).

Fields of papers citing papers by Céline Ségura‐Ferlay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Ségura‐Ferlay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Ségura‐Ferlay. The network helps show where Céline Ségura‐Ferlay may publish in the future.

Co-authorship network of co-authors of Céline Ségura‐Ferlay

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Ségura‐Ferlay. A scholar is included among the top collaborators of Céline Ségura‐Ferlay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Ségura‐Ferlay. Céline Ségura‐Ferlay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Fayette, Jérôme, Laurence Digue, Céline Ségura‐Ferlay, et al.. (2019). Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial. Annals of Oncology. 30. v455–v455. 6 indexed citations

Négrier, Sylvie, N. Costedoat‐Chalumeau, Alain Ravaud, et al.. (2018). Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap). Annals of Oncology. 29. viii307–viii307. 1 indexed citations

Ségura‐Ferlay, Céline, et al.. (2017). Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. Radiotherapy and Oncology. 126(2). 291–299. 17 indexed citations

Ghesquières, Hervé, Céline Ségura‐Ferlay, Gaëlle Fossard, et al.. (2015). Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution. Blood. 126(23). 1544–1544. 1 indexed citations

Marec‐Bérard, Perrine, Céline Ségura‐Ferlay, Marie‐Dominique Tabone, et al.. (2014). High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014. 1–7. 7 indexed citations

Nicolas‐Virelizier, Emmanuelle, Céline Ségura‐Ferlay, Hervé Ghesquières, et al.. (2014). Impact of the introduction of rituximab in first‐line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long‐term follow‐up. Hematological Oncology. 33(1). 1–8. 3 indexed citations

Terret, C., et al.. (2013). Sorafenib and sunitinib for elderly patients with renal cell carcinoma. Journal of Geriatric Oncology. 4(3). 255–261. 7 indexed citations

Pérol, M., C. Chouaïd, David Pérol, et al.. (2012). Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(28). 3516–3524. 166 indexed citations

Derbel, Olfa, Céline Ségura‐Ferlay, Jean‐Christophe Lifante, et al.. (2011). Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 11(1). 469–469. 66 indexed citations

10.

Ségura‐Ferlay, Céline, Thérèse Gargi, Catherine Chassagne‐Clément, et al.. (2011). Evaluation in the Context of Daily Practice of Follicular Lymphoma patients' Outcome Before and After Approval of Rituximab in First Line Therapy in This Indication: Results of a Retrospective Analysis of 247 Unselected Patients with a 5-Year Median of Follow-up,. Blood. 118(21). 3698–3698. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact